Study guide

2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery

Key Takeaways Explain This Topic AI

HPV vaccination is routinely recommended at ages 11 to 12, may start at age 9, and is given as a two-dose series when initiated before the 15th birthday and a three-dose series when initiated at or after age 15 or in immunocompromised patients.

Tobacco cessation is most effective when behavioral counseling is combined with pharmacotherapy; varenicline and combination nicotine replacement produce the highest quit rates.

Tamoxifen, raloxifene, and the aromatase inhibitors anastrozole and exemestane reduce invasive breast cancer incidence in high-risk women by roughly 40% to 65%, with tamoxifen the only option approved for premenopausal risk reduction.

Risk-reducing salpingo-oophorectomy is recommended at ages 35 to 40 for BRCA1 carriers and 40 to 45 for BRCA2 carriers after childbearing, and reduces ovarian cancer risk by more than 80%.

Aspirin reduces colorectal cancer incidence in Lynch syndrome carriers, and finasteride or dutasteride reduce overall prostate cancer detection but require explicit shared decision-making.

Last updated: August 2026

2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery

Blueprint focus: ONCC Domain I.A — prevention arm. Screening detects existing disease; primary prevention stops it from arising. The exam tests vaccination schedules, cessation pharmacotherapy, chemoprevention eligibility, and the ages at which risk-reducing surgery is offered.

1. Tobacco Cessation

Tobacco causes more cancer deaths than any other modifiable exposure, so cessation is the single highest-yield preventive act an oncology APRN performs — including in patients already diagnosed with cancer, where continued smoking worsens treatment toxicity, wound healing, second-primary risk, and survival.

Use the 5 A's : Ask, Advise, Assess, Assist, Arrange. Brief advice alone raises quit rates modestly; advice plus pharmacotherapy plus behavioral support roughly triples them.

Agent Typical regimen Key counseling point

Varenicline 0.5 mg daily × 3 days, 0.5 mg BID × 4 days, then 1 mg BID for 12 weeks Highest single-agent quit rate; start 1 week before quit date; counsel on vivid dreams and nausea

Combination nicotine replacement Long-acting patch plus a short-acting form (gum, lozenge, inhaler, nasal spray) Combination beats patch alone; match patch strength to cigarettes per day

Bupropion SR 150 mg daily × 3 days then 150 mg BID Avoid with seizure disorder or eating disorder history; useful when depression coexists

Extend pharmacotherapy beyond 12 weeks when relapse risk remains high, and treat relapse as an expected part of the process rather than a failure.

  • 2. Vaccination Against Oncogenic Infections
  • HPV vaccination

The 9-valent HPV vaccine prevents infection with the types responsible for nearly all cervical cancers and most oropharyngeal, anal, vulvar, vaginal, and penile squamous cancers.

Routine age: 11 to 12 years, and vaccination may begin at age 9 .

Two-dose schedule (0 and 6 to 12 months): when the first dose is given before the 15th birthday .

Three-dose schedule (0, 1 to 2, and 6 months): when the series starts at age 15 or older , or at any age in patients who are immunocompromised, including those with HIV or after transplant.

Catch-up is recommended through age 26. Between ages 27 and 45, vaccination is a shared clinical decision — benefit is smaller because many adults have already been exposed.

Vaccination does not replace cervical screening.

Hepatitis B vaccination

Universal infant vaccination plus adult vaccination through age 59 (and for at-risk adults 60 and older) prevents chronic infection and therefore hepatocellular carcinoma. Patients about to receive B-cell–depleting therapy such as rituximab must be screened for hepatitis B surface antigen and core antibody before treatment because of reactivation risk.

Helicobacter pylori eradication

Test-and-treat strategies in high-incidence populations and in patients with a first-degree relative with gastric cancer reduce gastric adenocarcinoma incidence.

3. Pharmacologic Chemoprevention

Chemoprevention means giving a drug to a person without cancer to lower the chance they develop it. Eligibility rests on a quantified risk estimate, and every conversation must weigh absolute benefit against the drug's own harms.

Breast cancer

Candidates are women aged 35 and older with a 5-year Gail-model risk of at least 1.67% , a history of lobular carcinoma in situ or atypical hyperplasia, or a strong family history.

Agent Population Risk reduction Principal harms

Tamoxifen 20 mg daily × 5 years Pre- or postmenopausal ~50% reduction in invasive ER-positive breast cancer Endometrial carcinoma, venous thromboembolism, cataracts, vasomotor symptoms

Raloxifene 60 mg daily × 5 years Postmenopausal only Somewhat less effective than tamoxifen for invasive disease Venous thromboembolism, hot flashes; no increase in endometrial cancer

Anastrozole or exemestane Postmenopausal only ~50% to 65% reduction Arthralgia, accelerated bone loss requiring DEXA monitoring

Because tamoxifen is the only option that works before menopause, a premenopausal patient with atypical hyperplasia who is offered "an aromatase inhibitor for prevention" is a classic distractor.

Colorectal cancer

Daily aspirin reduces long-term colorectal cancer incidence, and the effect is best established in Lynch syndrome , where regular aspirin has been shown to lower colorectal cancer incidence in randomized follow-up. Aspirin is not recommended as universal population chemoprevention because gastrointestinal and intracranial bleeding offset benefit in average-risk adults.

Prostate cancer

5-alpha-reductase inhibitors (finasteride, dutasteride) reduce the overall detection of prostate cancer but are not FDA-approved for prevention, and their use requires shared decision-making about the relative-risk trade-offs and PSA interpretation, since these drugs roughly halve measured PSA.

4. Risk-Reducing Surgery

Surgery is the most effective risk reduction available to carriers of high-penetrance variants, and its timing is heavily tested.

Procedure Indication Recommended timing Effect

Risk-reducing salpingo-oophorectomy (RRSO) BRCA1 Ages 35 to 40 , after childbearing Reduces ovarian, fallopian tube, and peritoneal cancer risk by more than 80%

RRSO BRCA2 Ages 40 to 45 (ovarian cancer onset is later) Same magnitude of ovarian risk reduction

Risk-reducing mastectomy BRCA1/2 , TP53 , PTEN , prior chest radiation before age 30 Individualized; elective Reduces breast cancer risk by more than 90%

Total hysterectomy with bilateral salpingo-oophorectomy Lynch syndrome After childbearing, typically around age 40 to 45 Eliminates endometrial and ovarian cancer risk

Total proctocolectomy or colectomy Familial adenomatous polyposis Late adolescence to early adulthood, once polyp burden is unmanageable endoscopically Prevents an otherwise near-certain colorectal cancer

Prophylactic thyroidectomy RET variant in multiple endocrine neoplasia type 2 Age determined by the specific RET codon Prevents medullary thyroid carcinoma

Premenopausal RRSO causes surgical menopause. Counsel proactively about vasomotor symptoms, bone density loss, cardiovascular risk, and sexual health, and discuss short-term hormone therapy for patients without a breast cancer history, since the balance of evidence supports it up to the natural age of menopause in that setting.

5. Structuring the Prevention Visit

Confirm risk category from Section 2.1 before selecting an intervention.

Deliver cessation advice with pharmacotherapy at every encounter with a current tobacco user.

Verify vaccination status against the age-appropriate HPV and hepatitis B schedule.

Quantify breast cancer risk with a validated model before discussing chemoprevention, and document the absolute benefit and absolute harm.

For carriers, name the specific surgery and its recommended age window , and coordinate fertility discussion before any procedure that ends reproductive capacity.

Loading diagram... Selecting a Primary Prevention Strategy